Abbisko Cayman (HKG:2256) forecasts it will turn to a profit of 10 million yuan in 2024 from a loss of 432 million yuan in the year-ago period, according to a Monday filing with the Hong Kong Exchange.
Revenue is also seen to surge to 504 million yuan in 2024 from 19 million yuan in 2023, the filing said.
The rise is attributable to better cost control and efficiency, as well as an upfront payment of $70 million from the out-licensing agreement with Merck for pimicotinib, the filing said.
Shares surged 5% during Monday's morning trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.